|

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

RECRUITINGPhase 2Sponsored by Zhejiang Cancer Hospital
Actively Recruiting
PhasePhase 2
SponsorZhejiang Cancer Hospital
Started2023-09-28
Est. completion2024-09-30
Eligibility
Age65 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06055816

Summary

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Eligibility

Age: 65 Years+Healthy volunteers accepted
Inclusion Criteria:

* Aged ≥65 years with newly pathologically confirmed NPC
* Karnofsky performance status ≥60
* Clinical stage III-IVA (Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, 8th edition)
* Adequate organ function

Exclusion Criteria:

* Cancer history
* Prior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy
* Life-expectance within 6 months

Conditions2

CancerNasopharyngeal Carcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.